The September issue of ONCOLOGY features work on the implementation to multidisciplinary care and barriers to overcome it, a study that looked at the FDA REMs mandate, and an in-depth look of tisotumab vedotin in cervical cancer. https://lnkd.in/eE3rMa99
About us
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers. Contact us at: [email protected] Like us on Facebook: Cancer Network Follow us on Twitter: @CancerNetwrk
- Website
-
http://www.cancernetwork.com
External link for Cancer Network
- Industry
- Book and Periodical Publishing
- Company size
- 201-500 employees
- Headquarters
- Cranbury, New Jersey
- Type
- Privately Held
Locations
-
Primary
Cranbury, New Jersey 08512, US
Employees at Cancer Network
Updates
-
The FDA has granted priority review to a supplemental new drug application for acalabrutinib as a therapy for patients with previously untreated mantle cell lymphoma. FDA https://lnkd.in/e96v6j_H #lymsm #cancer #oncology
-
Cancer Network reposted this
Do you know an oncology nurse who has made a lasting impact? We want to hear your story! Nominate a nurse who has gone above and beyond by sharing a specific moment when they truly made a difference. This is more than just a nomination—it's an opportunity to tell a meaningful story about an extraordinary healer. Three finalists and their nominators will be celebrated at a special reception during the Oncology Nursing Society's 50th Annual Congress, and one exceptional nurse will be named the 2025 Extraordinary Healer® and honored by our celebrity keynote speaker. Share your story and nominate a deserving nurse today: https://ow.ly/9WMu50TBaYv #oncologynursing #healthcarehero #cancercar\\oncology
-
Thomas Martin, MD, contextualized the BENEFIT trial by describing how bortezomib was being evaluated for its effect on multiple myeloma treatment. https://lnkd.in/eF_q_4kJ #mmsm #cance #oncology
-
Of 178 patients who underwent treatment with BCS plus radiotherapy, the test identified 113 as having residual risk subtype disease, 28 as having low-risk disease, and 37 as having elevated-risk disease. https://lnkd.in/eR48bRDH #bcsm #cancer #oncology
Biosignature Test May Predict Residual Risk Post-BCS/RT in HER2+ DCIS
cancernetwork.com
-
FDA approves neoadjuvant/adjuvant nivolumab plus chemotherapy in resectable EGFR/ALK NSCLC. https://lnkd.in/e5M8aP7s #NSCLC #cancer #oncology
Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC
cancernetwork.com
-
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies. American Society for Radiation Oncology (ASTRO) https://lnkd.in/eq5YkD6r #cancer #oncology
Retrospective Radiotherapy in IBD Data May Warrant Prospective Research
cancernetwork.com
-
Samantha Shenoy, NP, outlined the importance nurses play in communicating to providers the presence of adverse effects related to talquetamab treatment. University of California, San Francisco https://lnkd.in/egYVvJmG #mmsm #cancer #oncology
Assessing NP Roles in Talquetamab Treatment for Multiple Myeloma
cancernetwork.com
-
After at least 1 year of follow-up across the ITT population, marginal failure occurred in 4% of patients, yielding non-inferiority compared with historical rates of marginal failure (P < .001). American Society for Radiation Oncology (ASTRO) https://lnkd.in/eK6MjSyw #btsm #cancer #oncology
Adaptive Radiotherapy Modality Appears Safe, Feasible in High-Grade Glioma
cancernetwork.com
-
#Sponsored Hackensack Meridian John Theurer Cancer Center, named NJ’s best cancer center by U.S. News & World Report, now offers SCINTIX™ PET scan-guided radiation therapy. This cutting-edge technology targets cancer with pinpoint accuracy, often in just one treatment, while sparing healthy tissue. Learn more about this revolutionary approach to cancer care. Learn more- https://lnkd.in/eqHBaeqk